L6 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:63611 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER: 146:148846
TITLE: Pharmaceutical propylene glycol solvate compositions and method for preparation thereof
INVENTOR(S): Tawa, Mark; Almarsson, Orn; Remenar, Julius
PATENT ASSIGNEE(S): Transform Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 33pp., Cont.-in-part of Appl. No. PCT/US03/41273.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 18
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007015841	A1	20070118	US 2003-747742	20031229 <--
US 6559293	B1	20030506	US 2002-232589	20020903
US 2003166581	A1	20030904	US 2002-295995	20021118
US 6699840	B2	20040302		
US 2003224006	A1	20031204	US 2003-378956	20030303
US 2004019211	A1	20040129	US 2003-449307	20030530
US 7078526	B2	20060718		
WO 2004000284	A1	20031231	WO 2003-US19574	20030620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005025791	A1	20050203	US 2003-601092	20030620
US 2004053853	A1	20040318	US 2003-637829	20030808
WO 2004078161	A1	20040916	WO 2003-US27772	20030904
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2007026078	A1	20070201	US 2003-660202	20030911
WO 2004061433	A1	20040722	WO 2003-US41273	20031224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004063152	A2	20040729	WO 2004-US400	20040108

WO 2004063152 A3 20041111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ
WO 2004089313 A2 20041021 WO 2004-US9947 20040331
WO 2004089313 A3 20051124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
ZA 2004007377 A 20051004 ZA 2004-7377 20040914
US 2006140985 A1 20060629 US 2005-541703 20050708
PRIORITY APPLN. INFO.: US 2002-356764P P 20020215
US 2002-360768P P 20020301
US 2002-380288P P 20020515
US 2002-384152P P 20020531
US 2002-390881P P 20020621
US 2002-406974P P 20020830
US 2002-232589 A1 20020903
US 2002-426275P P 20021114
US 2002-427086P P 20021115
US 2002-295995 A3 20021118
US 2002-428515P P 20021122
US 2002-429515P P 20021126
US 2002-437516P P 20021230
US 2003-439282P P 20030110
US 2003-441335P P 20030121
US 2003-444315P P 20030131
US 2003-451213P P 20030228
US 2003-378956 A2 20030303
US 2003-456027P P 20030318
US 2003-456608P P 20030321
US 2003-459501P P 20030401
US 2003-463962P P 20030418
US 2003-449307 A2 20030530
US 2003-601092 A2 20030620
WO 2003-US19574 A2 20030620
US 2003-486713P P 20030711
US 2003-487064P P 20030711
US 2003-637829 A2 20030808
WO 2003-US27772 A2 20030904
US 2003-660202 A2 20030911
WO 2003-US41273 A2 20031224
US 2003-439283P P 20030110
WO 2003-US28982 A2 20030916
US 2003-747742 A 20031229
WO 2003-US41642 A 20031229
WO 2004-US400 W 20040108
WO 2004-US6288 A 20040226
US 2004-548343P P 20040227

AB The present invention provides a pharmaceutical composition comprising a propylene glycol solvate of a drug which is hygroscopic or has low aqueous solubility It has surprisingly been found that by using propylene glycol to form a solvate of a hygroscopic drug, the hygroscopicity of the drug is

decreased and/or the stability and aqueous solubility is increased. The drug is therefore much easier to formulate and store than its counterpart untreated or hydrated form.

IT 169590-42-5, Celecoxib
RL: RCT (Reactant); RACT (Reactant or reagent)
(pharmaceutical propylene glycol solvate compns. and method for preparation thereof)

RN 169590-42-5 HCAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



IT 639010-40-5P 919287-67-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(pharmaceutical propylene glycol solvate compns. and method for preparation thereof)

RN 639010-40-5 HCAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, sodium salt, compd. with 1,2-propanediol, hydrate (1:1:1:3) (CA INDEX NAME)

CM 1

CRN 169590-42-5
CMF C17 H14 F3 N3 O2 S



CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 919287-67-5 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, sodium salt, compd. with 1,2-propanediol (1:1:1) (CA INDEX NAME)

CM 1

CRN 169590-42-5
CMF C17 H14 F3 N3 O2 S



CM 2

CRN 57-55-6
CMF C3 H8 O2



IT 639010-33-6, Celecoxib sodium 639010-34-7, Celecoxib lithium 639010-35-8, Celecoxib potassium
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical propylene glycol solvate compns. and method for preparation thereof)
RN 639010-33-6 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 639010-34-7 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, lithium salt (1:1) (CA INDEX NAME)



● Li

RN 639010-35-8 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, potassium salt (1:1) (CA INDEX NAME)



● K

L6 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:754423 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER: 141:282787
TITLE: Pharmaceutical cocrystal compositions of drugs such as carbamazepine, celecoxib, and olanzapine
INVENTOR(S): Almarsson, Oern; Bourghol Hickey, Magali; Peterson, Matthew; Zaworotko, Michael J.; Moulton, Brian; Rodriguez-Hornedo, Nair
PATENT ASSIGNEE(S): Transform Pharmaceuticals, Inc., USA; University of South Florida; The Regents of the University of Michigan
SOURCE: PCT Int. Appl., 489 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 18
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078161	A1	20040916	WO 2003-US27772	20030904
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003224006	A1	20031204	US 2003-378956	20030303
CA 2513746	A1	20040916	CA 2003-2513746	20030904
AU 2003272270	A1	20040928	AU 2003-272270	20030904
EP 1608339	A1	20051228	EP 2003-754445	20030904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2007507554	T	20070329	JP 2006-552403	20030904
US 2007026078	A1	20070201	US 2003-660202	20030911
CA 2511881	A1	20040722	CA 2003-2511881	20031224
WO 2004061433	A1	20040722	WO 2003-US41273	20031224

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003303591 A1 20040729 AU 2003-303591 20031224
EP 1579198 A1 20050928 EP 2003-808567 20031224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2006517527 T 20060727 JP 2005-508617 20031224
US 2007015841 A1 20070118 US 2003-747742 20031229 <--
CA 2514733 A1 20040916 CA 2004-2514733 20040226
WO 2004078163 A2 20040916 WO 2004-US6288 20040226
WO 2004078163 A3 20050120
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG
EP 1631260 A2 20060308 EP 2004-715190 20040226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2007524596 T 20070830 JP 2006-508979 20040226
WO 2004089313 A2 20041021 WO 2004-US9947 20040331
WO 2004089313 A3 20051124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

US 2005070551 A1 20050331 US 2004-926842 20040826
AU 2004270238 A1 20050317 AU 2004-270238 20040904
CA 2534664 A1 20050317 CA 2004-2534664 20040904
WO 2005023198 A2 20050317 WO 2004-US29013 20040904
WO 2005023198 A3 20050714
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NA, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, TZ, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG
EP 1670753 A2 20060621 EP 2004-783308 20040904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

BR	2004013777	A	20061107	BR	2004-13777		20040904
CN	1874993	A	20061206	CN	2004-80031982		20040904
JP	2007513867	T	20070531	JP	2006-525508		20040904
US	2006134198	A1	20060622	US	2005-541216		20050629
US	2006140985	A1	20060629	US	2005-541703		20050708
US	2007059356	A1	20070315	US	2005-546963		20050826
US	2006223794	A1	20061005	US	2005-551014		20050929
IN	2006KN00371	A	20070622	IN	2006-KN371		20060220
US	2007021510	A1	20070125	US	2006-570405		20060303
PRIORITY APPLN. INFO.:				US	2003-451213P	P	20030228
				US	2003-378956	A	20030303
				US	2003-463962P	P	20030418
				US	2003-487064P	P	20030711
				US	2002-356764P	P	20020215
				US	2002-360768P	P	20020301
				US	2002-380288P	P	20020515
				US	2002-384152P	P	20020531
				US	2002-390881P	P	20020621
				US	2002-406974P	P	20020830
				US	2002-232589	A1	20020903
				US	2002-426275P	P	20021114
				US	2002-427086P	P	20021115
				US	2002-295995	A3	20021118
				US	2002-428515P	P	20021122
				US	2002-429515P	P	20021126
				US	2002-437516P	P	20021230
				US	2003-439282P	P	20030110
				US	2003-439283P	P	20030110
				US	2003-441335P	P	20030121
				US	2003-444315P	P	20030131
				WO	2003-US306662	A	20030303
				WO	2003-US6662	A	20030303
				US	2003-456027P	P	20030318
				US	2003-456608P	P	20030321
				US	2003-459501P	P	20030401
				US	2003-449307	A2	20030530
				WO	2003-US17184	A2	20030530
				US	2003-601092	A2	20030620
				WO	2003-US19574	A	20030620
				WO	2003-US319574	A	20030620
				US	2003-486713P	P	20030711
				US	2003-637829	A2	20030808
				WO	2003-US27772	W	20030904
				WO	2003-US327772	A	20030904
				US	2003-660202	A	20030911
				WO	2003-US28982	A	20030916
				US	2003-508208P	P	20031002
				WO	2003-US341273	A	20031224
				WO	2003-US41273	W	20031224
				US	2003-747742	A	20031229
				US	2004-747742	A1	20031229
				WO	2003-US341642	A	20031229
				WO	2003-US41642	A	20031229
				WO	2004-US400	W	20040108
				US	2004-542752P	P	20040206
				WO	2004-US6288	W	20040226
				US	2004-548343P	P	20040227
				WO	2004-US9947	W	20040331
				US	2004-560411P	P	20040406
				US	2004-573412P	P	20040521
				US	2004-579176P	P	20040612

US 2004-581992P	P	20040622
US 2004-586752P	P	20040709
US 2004-588236P	P	20040715
US 2004-590590P	P	20040723
WO 2004-US29013	W	20040904

AB A pharmaceutical composition comprising a cocrystal of an active pharmaceutical ingredient (API) and a cocrystal forming compound wherein the API has at least 1 functional group selected from, e.g., ether, thioether, alc., thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, amine, secondary amine, ammonia, imidazole, or pyridine and the co-crystal forming compound has at least 1 functional group selected from e.g., amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, or sulfone,, such that the API and cocrystal forming compound are capable of co-crystallizing from a solution phase under crystallization conditions. Thus, carbamazepine and p-phthalaldehyde were dissolved in MeOH and slow evaporation of the solvent gave 1:1 carbamazepine-p-phthalaldehyde cocrystals. The cocrystals were characterized by powder x-ray diffraction, DSC and IR spectrometry.

IT 169590-42-5, Celecoxib
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(pharmaceutical cocrystal compns. of drugs such as carbamazepine and celecoxib and olanzapine)

RN 169590-42-5 HCAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2004:589730 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER:	141:145692
TITLE:	Pharmaceutical compositions with improved dissolution
INVENTOR(S):	Tawa, Mark; Remenar, Julius; Peterson, Matthew; Almarsson, Orn; Guzman, Hector; Chen, Hongming; Oliveira, Mark
PATENT ASSIGNEE(S):	Transform Pharmaceuticals, Inc., USA
SOURCE:	PCT Int. Appl., 257 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	18
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004061433	A1	20040722	WO 2003-US41273	20031224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003224006	A1	20031204	US 2003-378956	20030303
US 2004019211	A1	20040129	US 2003-449307	20030530
US 7078526	B2	20060718		
WO 2004000284	A1	20031231	WO 2003-US19574	20030620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005025791	A1	20050203	US 2003-601092	20030620
US 2004053853	A1	20040318	US 2003-637829	20030808
WO 2004078161	A1	20040916	WO 2003-US27772	20030904
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2007026078	A1	20070201	US 2003-660202	20030911
WO 2004026235	A2	20040401	WO 2003-US28982	20030916
WO 2004026235	A3	20040805		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2511881	A1	20040722	CA 2003-2511881	20031224
AU 2003303591	A1	20040729	AU 2003-303591	20031224
EP 1579198	A1	20050928	EP 2003-808567	20031224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006517527	T	20060727	JP 2005-508617	20031224
WO 2004060347	A2	20040722	WO 2003-US41642	20031229
WO 2004060347	A3	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2003300452	A1	20040729	AU	2003-300452	20031229
US	2007015841	A1	20070118	US	2003-747742	20031229 <--
CA	2514733	A1	20040916	CA	2004-2514733	20040226
WO	2004078163	A2	20040916	WO	2004-US6288	20040226
WO	2004078163	A3	20050120			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG

EP	1631260	A2	20060308	EP	2004-715190	20040226
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP	2007524596	T	20070830	JP	2006-508979	20040226
US	2006134198	A1	20060622	US	2005-541216	20050629
US	2006140985	A1	20060629	US	2005-541703	20050708
US	2007059356	A1	20070315	US	2005-546963	20050826
US	2006223794	A1	20061005	US	2005-551014	20050929

PRIORITY APPLN. INFO.:

US	2002-437516P	P 20021230
US	2003-441335P	P 20030121
US	2003-451213P	P 20030228
US	2003-378956	A 20030303
US	2003-456027P	P 20030318
US	2003-456608P	P 20030321
US	2003-459501P	P 20030401
US	2003-449307	A 20030530
US	2003-601092	A2 20030620
WO	2003-US19574	A2 20030620
US	2003-486713P	P 20030711
US	2003-487064P	P 20030711
US	2003-637829	A 20030808
WO	2003-US27772	A2 20030904
US	2003-660202	A2 20030911
WO	2003-US28982	A2 20030916
US	2002-356764P	P 20020215
US	2002-360768P	P 20020301
US	2002-380288P	P 20020515
US	2002-384152P	P 20020531
US	2002-390881P	P 20020621
US	2002-406974P	P 20020830
US	2002-232589	A1 20020903
US	2002-412459P	P 20020920
US	2002-426275P	P 20021114
US	2002-427086P	P 20021115
US	2002-295995	A1 20021118
US	2002-428515P	P 20021122
US	2002-429515P	P 20021126
US	2003-439282P	P 20030110
US	2003-439283P	P 20030110
US	2003-444315P	P 20030131

WO	2003-US306662	A	20030303
WO	2003-US6662	A	20030303
US	2003-463962P	P	20030418
WO	2003-US319574	A	20030620
WO	2003-US327772	A	20030904
US	2003-508208P	P	20031002
WO	2003-US341273	A	20031224
WO	2003-US41273	W	20031224
US	2004-747742	A1	20031229
WO	2003-US341642	A	20031229
WO	2003-US41642	W	20031229
WO	2004-US400	W	20040108
US	2004-542752P	P	20040206
WO	2004-US6288	W	20040226
WO	2004-US9947	W	20040331

AB The invention relates to methods of screening mixts. containing a pharmaceutical and an excipient to identify properties of the pharmaceutical/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissoln. and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a precipitation retardant and an optional enhancer. Thus, a celecoxib hydrate or solvate was prepd.and its dissoln. and crystal properties were determined

IT 639010-33-6P, Celecoxib sodium
RL: PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. with improved dissoln.)

RN 639010-33-6 HCAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, sodium salt (1:1) (CA INDEX NAME)



● Na

IT 639010-42-7
RL: PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. with improved dissoln.)

RN 639010-42-7 HCAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, monosodium salt, hydrate (9CI) (CA INDEX NAME)



● x H_2O

● Na

IT 169590-42-5, Celecoxib
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. with improved dissoln.)
RN 169590-42-5 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



IT 639010-34-7P, Celecoxib lithium 639010-35-8P, Celecoxib potassium 639010-36-9P, Celecoxib calcium 639010-38-1P 639010-39-2P 639010-40-5P 919287-67-5P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. with improved dissoln.)
RN 639010-34-7 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, lithium salt (1:1) (CA INDEX NAME)



● Li

RN 639010-35-8 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, potassium salt (1:1) (CA INDEX NAME)



● K

RN 639010-36-9 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

RN 639010-38-1 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, monopotassium salt, compd. with 1,2-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 639010-35-8
CMF C17 H14 F3 N3 O2 S . K



● K

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 639010-39-2 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, monolithium salt, compd. with 1,2-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 639010-34-7
CMF C17 H14 F3 N3 O2 S . Li



CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 639010-40-5 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, sodium salt, compd. with 1,2-propanediol, hydrate (1:1:1:3) (CA INDEX NAME)

CM 1

CRN 169590-42-5
CMF C17 H14 F3 N3 O2 S



CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 919287-67-5 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, sodium salt, compd. with 1,2-propanediol (1:1:1) (CA INDEX NAME)

CM 1

CRN 169590-42-5
CMF C17 H14 F3 N3 O2 S



CM 2

CRN 57-55-6
CMF C3 H8 O2



IT 9004-34-6D, Cellulose, esters 106392-12-5, Poloxamer
162011-90-7, Rofecoxib 169590-41-4, Deracoxib
181695-72-7, Valdecoxib 202409-33-4, Etoricoxib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. with improved dissoln.)
RN 9004-34-6 HCAPLUS
CN Cellulose (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 106392-12-5 HCAPLUS
CN Oxirane, 2-methyl-, polymer with oxirane, block (CA INDEX NAME)

CM 1

CRN 75-56-9
CMF C3 H6 O

CM 2

CRN 75-21-8
CMF C2 H4 O

RN 162011-90-7 HCAPLUS
CN 2(5H)-Furanone, 4-[4-(methylsulfonyl)phenyl]-3-phenyl- (CA INDEX NAME)



RN 169590-41-4 HCAPLUS
CN Benzenesulfonamide, 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-

pyrazol-1-yl]- (CA INDEX NAME)



RN 181695-72-7 HCAPLUS
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (CA INDEX NAME)



RN 202409-33-4 HCAPLUS
CN 2,3'-Bipyridine, 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



L6 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:2673 HCAPLUS <<LOGINID::20080310>>

DOCUMENT NUMBER: 140:65197
TITLE: Pharmaceutical compositions with improved dissolution
INVENTOR(S): Remenar, Julius; Peterson, Matthew; Almarsson, Orn; Guzman, Hector; Chen, Hongming; Tawa, Mark; Olivera, Mark
PATENT ASSIGNEE(S): Transform Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 18
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000284	A1	20031231	WO 2003-US19574	20030620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2489984	A1	20031231	CA 2003-2489984	20030620
AU 2003243699	A1	20040106	AU 2003-243699	20030620
BR 2003005421	A	20040928	BR 2003-5421	20030620
EP 1515703	A1	20050323	EP 2003-761203	20030620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1668283	A	20050914	CN 2003-817148	20030620
JP 2006500377	T	20060105	JP 2004-530963	20030620
CA 2511881	A1	20040722	CA 2003-2511881	20031224
WO 2004061433	A1	20040722	WO 2003-US41273	20031224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003303591	A1	20040729	AU 2003-303591	20031224
EP 1579198	A1	20050928	EP 2003-808567	20031224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006517527	T	20060727	JP 2005-508617	20031224
WO 2004060347	A2	20040722	WO 2003-US41642	20031229
WO 2004060347	A3	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,				

TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2003300452	A1	20040729	AU	2003-300452	20031229
US	2007015841	A1	20070118	US	2003-747742	20031229 <--
CA	2514733	A1	20040916	CA	2004-2514733	20040226
WO	2004078163	A2	20040916	WO	2004-US6288	20040226
WO	2004078163	A3	20050120			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP	1631260	A2	20060308	EP	2004-715190	20040226

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP	2007524596	T	20070830	JP	2006-508979	20040226
IN	2004CN02835	A	20060210	IN	2004-CN2835	20041215
MX	2005PA00232	A	20050617	MX	2005-PA232	20050103
US	2006134198	A1	20060622	US	2005-541216	20050629
US	2006140985	A1	20060629	US	2005-541703	20050708
US	2007059356	A1	20070315	US	2005-546963	20050826
US	2006223794	A1	20061005	US	2005-551014	20050929

PRIORITY APPLN. INFO.:

US	2002-390881P	P	20020621
US	2002-426275P	P	20021114
US	2002-427086P	P	20021115
US	2002-429515P	P	20021126
US	2002-437516P	P	20021230
US	2003-456027P	P	20030318
US	2002-356764P	P	20020215
US	2002-360768P	P	20020301
US	2002-380288P	P	20020515
US	2002-384152P	P	20020531
US	2002-406974P	P	20020830
US	2002-232589	A	20020903
US	2002-295995	A3	20021118
US	2002-428515P	P	20021122
US	2003-439282P	P	20030110
US	2003-439283P	P	20030110
US	2003-441335P	P	20030121
US	2003-444315P	P	20030131
US	2003-451213P	P	20030228
US	2003-378956	A	20030303
WO	2003-US306662	A	20030303
WO	2003-US6662	A	20030303
US	2003-456608P	P	20030321
US	2003-459501P	P	20030401
US	2003-463962P	P	20030418
US	2003-449307	A	20030530
US	2003-601092	A	20030620
WO	2003-US19574	W	20030620
WO	2003-US319574	A	20030620
US	2003-486713P	P	20030711
US	2003-487064P	P	20030711
US	2003-637829	A	20030808
WO	2003-US27772	A	20030904
WO	2003-US327772	A	20030904
US	2003-660202	A	20030911
WO	2003-US28982	A	20030916
US	2003-508208P	P	20031002
WO	2003-US341273	A	20031224

WO 2003-US41273	W	20031224
US 2004-747742	A1	20031229
WO 2003-US341642	A	20031229
WO 2003-US41642	W	20031229
WO 2004-US400	W	20040108
US 2004-542752P	P	20040206
WO 2004-US6288	W	20040226
WO 2004-US9947	W	20040331

AB The invention relates to methods of screening mixts. containing a pharmaceutical compound an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissoln. and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a recrystn./precipitation retardant and an optional enhancer. Thus, celecoxib sodium salt was prepared by dissolving celecoxib in 1N NaOH solution The product was characterized by PXRD, DSC and TGA.

IT 639010-33-6P 639010-34-7P 639010-35-8P
639010-36-9P 639010-38-1P 919287-67-5P
RL: PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. with improved dissoln.)

RN 639010-33-6 HCAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, sodium salt (1:1) (CA INDEX NAME)



RN 639010-34-7 HCAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, lithium salt (1:1) (CA INDEX NAME)



● Li

RN 639010-35-8 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, potassium salt (1:1) (CA INDEX NAME)



● K

RN 639010-36-9 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

RN 639010-38-1 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, monopotassium salt, compd. with 1,2-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 639010-35-8
CMF C17 H14 F3 N3 O2 S . K



● K

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 919287-67-5 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, sodium salt, compd. with 1,2-propanediol (1:1:1) (CA INDEX NAME)

CM 1

CRN 169590-42-5
CMF C17 H14 F3 N3 O2 S



CM 2

CRN 57-55-6
CMF C3 H8 O2



IT 169590-42-5, Celecoxib
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. with improved dissoln.)
RN 169590-42-5 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



IT 639010-39-2P 639010-40-5P 639010-41-6P
639010-42-7P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. with improved dissoln.)

RN 639010-39-2 HCAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, monolithium salt, compd. with 1,2-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 639010-34-7
CMF C17 H14 F3 N3 O2 S . Li



CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 639010-40-5 HCAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, sodium salt, compd. with 1,2-propanediol, hydrate (1:1:1:3) (CA INDEX NAME)

CM 1

CRN 169590-42-5
CMF C17 H14 F3 N3 O2 S



CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 639010-41-6 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, monosodium salt, compd. with 2-propanol (9CI) (CA INDEX NAME)

CM 1

CRN 169590-42-5
CMF C17 H14 F3 N3 O2 S



CM 2

CRN 67-63-0
CMF C3 H8 O

RN 639010-42-7 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, monosodium salt, hydrate (9CI) (CA INDEX NAME)



IT 9004-34-6D, Cellulose, esters 9004-64-2, Hydroxypropyl cellulose 9004-65-3, HPMC 9004-96-0, Polyethylene glycol monooleate 106392-12-5, Poloxamer 162011-90-7, Rofecoxib 169590-41-4, Deracoxib 181695-72-7, Valdecoxib 202409-33-4, Etoricoxib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. with improved dissoln.)
RN 9004-34-6 HCAPLUS
CN Cellulose (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9004-64-2 HCAPLUS
CN Cellulose, 2-hydroxypropyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2

RN 9004-65-3 HCAPLUS
CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O

CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9004-96-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-[(9Z)-1-oxo-9-octadecen-1-yl]-ω-hydroxy- (CA INDEX NAME)



RN 106392-12-5 HCAPLUS
CN Oxirane, 2-methyl-, polymer with oxirane, block (CA INDEX NAME)

CM 1

CRN 75-56-9
CMF C3 H6 O

CM 2

CRN 75-21-8
CMF C2 H4 O

RN 162011-90-7 HCAPLUS
CN 2(5H)-Furanone, 4-[4-(methylsulfonyl)phenyl]-3-phenyl- (CA INDEX NAME)



RN 169590-41-4 HCAPLUS
CN Benzenesulfonamide, 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 181695-72-7 HCAPLUS
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (CA INDEX NAME)



RN 202409-33-4 HCAPLUS
CN 2,3'-Bipyridine, 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



L13 ANSWER 1 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1238781 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER: 147:491657
TITLE: Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof
INVENTOR(S): Jain, Rajesh; Jindal, Kour Chand
PATENT ASSIGNEE(S): Panacea Biotec Ltd., India
SOURCE: PCT Int. Appl., 40pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007122637	A1	20071101	WO 2007-IN162	20070423

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

IN 2006DE01033 A 20080118 IN 2006-DE1033 20060424

PRIORITY APPLN. INFO.: IN 2006-DE1033 A 20060424

AB Low dose pharmaceutical dosage form comprising nimesulide or its pharmaceutically acceptable salts, esters, solvates or hydrates thereof, along with one or more pharmaceutically acceptable excipient(s) for once- or twice-a-day administration are provided. The present invention also provides process of preparing such dosage forms and therapeutic methods of using such dosage forms. The low dose compns. are designed to exhibit bioavailability with reduced side effects, which is effective in the treatment of NSAID indicated disorders particularly, which require long-term treatment regimens such as arthritis. Such compns. reduce the cost of therapy in diseases, which require long-term therapies, are easy to manufacture, and also result in the reduction of dose related side effects associated with nimesulide therapy. Thus, tablets containing nimesulide 75.0 mg, microcryst. cellulose 285.0 mg, lactose 100.0 mg, croscarmellose sodium 20.0 mg, hydrogenated castor oil 7.5 mg, talc 7.5 mg, and colloidal silica 7.5 mg were prepared by wet granulation using iso-Pr alc. and compression.

IT 57-55-6, Propylene glycol, biological studies 57-55-6D, Propylene glycol, C8-10 diesters
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(low-dose nimesulide compns. optionally in combination with other agents for treatment of inflammation and related disorders)

RN 57-55-6 HCAPLUS

CN 1,2-Propanediol (CA INDEX NAME)



RN 57-55-6 HCAPLUS

CN 1,2-Propanediol (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:845664 HCAPLUS <<LOGINID::20080310>>

DOCUMENT NUMBER: 147:220080

TITLE: Novel oral pharmaceutical compositions for poorly absorbable drugs comprising adsorbents, bioadhesive polymers, and permeation enhancers

INVENTOR(S): Jain, Rajesh; Jindal, Kour Chand; Devarajan, Sampath Kumar

PATENT ASSIGNEE(S): Panacea Biotec Ltd., India

SOURCE: PCT Int. Appl., 41pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007086078	A2	20070802	WO 2007-IN29	20070129
WO 2007086078	A3	20071213		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: IN 2006-DE242 A 20060130

AB Novel oral pharmaceutical compns. comprising (i) at least one active agent(s) or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates, analogs, enantiomers, tautomeric forms or mixts. thereof; (ii) at least one permeation enhancer(s); (iii) at least one adsorbent(s), (iv) at least one bioadhesive polymer(s); (v) optionally at least one acid soluble polymer(s), and (vi) optionally one or more other pharmaceutically acceptable excipient(s) are provided. The active agents exhibit poor or incomplete absorption, are preferably absorbed from the upper part of the gastrointestinal tract, and/or exhibit dissoln. rate with limited gastrointestinal absorption. The compns. particularly target the absorption window of the active agent(s) delivering the active agent at the absorption site preferably over an extended period of time to enhance their bioavailability. Preferably the compns. are in the gastro-adhesive modified release form and/or fast disintegrating dosage form which release the active agent(s) over an extended period of time. Also provided are processes of preparation of such novel compns. and methods of using them. Thus, tablets were prepared comprising (a) a core composition containing amoxicillin trihydrate 500.0, glyceryl monocaprylate 60.0, microcryst. cellulose (Avicel PH 102) 100.0, sodium alginate 100.0, hydroxypropyl Me cellulose 50.0, anhydrous lactose (Pharmatose DCL 21) 42.3, and magnesium stearate 5.0, (b) a coating composition containing Eudragit E100 85.5, triacetin 8.5, talc 37.7, isopropanol as needed, and acetone as needed, and (c) an extragranular composition containing calcium CM-cellulose 100.0, Avicel PH 102 100.0, and magnesium stearate 10.0 mg, resp. The cores, prepared by dry granulation, were coated, mixed with the extragranular composition and compressed into tablets.

IT 57-55-6, Propylene glycol, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral pharmaceutical compns. for poorly absorbable drugs comprising adsorbent, bioadhesive polymer and permeation enhancers)

RN 57-55-6 HCAPLUS

CN 1,2-Propanediol (CA INDEX NAME)



L13 ANSWER 3 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:618382 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER: 147:57851
TITLE: Mixtures comprising anthranilic acid amides and antidandruff agents as cosmetic and pharmaceutical compositions for alleviating itching
INVENTOR(S): Schmaus, Gerhard; Roeding, Joachim
PATENT ASSIGNEE(S): Symrise G.m.b.H. & Co. K.-G., Germany
SOURCE: PCT Int. Appl., 70pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007062957	A1	20070607	WO 2006-EP68077	20061103

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-740690P P 20051130
OTHER SOURCE(S): MARPAT 147:57851
GI



I

AB The invention relates to a mixture comprising or consisting of (a) one or more compds. of Formula I (R1, R2 = H or together form another bond; R3 = H, alkyl; X, Y = OH, O-alkyl, O-acyl; m = 0-3; n, p = 0-2) or cosmetically or pharmaceutically acceptable salts and solvates thereof, and (b) one or more antidandruff agents. Thus, a shampoo formulation containing 0.2% antidandruff compound climbazole and 0.05% the itch-alleviating compound dihydroavenanthramide D showed better efficacy in reducing scalp itching in subjects compared to a shampoo containing antidandruff compound only. After 42 days, the intensity of itching could be reduced from 4.1 to a value of 2.4 on the itching scale of 1 to 6.

IT 57-55-6, Propylene glycol, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising mixts. of anthranilic acid amides and antidandruff agents for alleviating itching)

RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (CA INDEX NAME)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:63611 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER: 146:148846
TITLE: Pharmaceutical propylene glycol solvate compositions and method for preparation thereof
INVENTOR(S): Tawa, Mark; Almarsson, Orn; Remenar, Julius
PATENT ASSIGNEE(S): Transform Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 33pp., Cont.-in-part of Appl. No. PCT/US03/41273.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 18
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007015841	A1	20070118	US 2003-747742	20031229
US 6559293	B1	20030506	US 2002-232589	20020903
US 2003166581	A1	20030904	US 2002-295995	20021118
US 6699840	B2	20040302		
US 2003224006	A1	20031204	US 2003-378956	20030303
US 2004019211	A1	20040129	US 2003-449307	20030530
US 7078526	B2	20060718		
WO 2004000284	A1	20031231	WO 2003-US19574	20030620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005025791	A1	20050203	US 2003-601092	20030620
US 2004053853	A1	20040318	US 2003-637829	20030808
WO 2004078161	A1	20040916	WO 2003-US27772	20030904
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2007026078	A1	20070201	US 2003-660202	20030911
WO 2004061433	A1	20040722	WO 2003-US41273	20031224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO	2004063152	A2	20040729	WO 2004-US400	20040108
WO	2004063152	A3	20041111		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ

WO	2004089313	A2	20041021	WO 2004-US9947	20040331
WO	2004089313	A3	20051124		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

ZA	2004007377	A	20051004	ZA 2004-7377	20040914
US	2006140985	A1	20060629	US 2005-541703	20050708

PRIORITY APPLN. INFO.:

US 2002-356764P	P	20020215
US 2002-360768P	P	20020301
US 2002-380288P	P	20020515
US 2002-384152P	P	20020531
US 2002-390881P	P	20020621
US 2002-406974P	P	20020830
US 2002-232589	A1	20020903
US 2002-426275P	P	20021114
US 2002-427086P	P	20021115
US 2002-295995	A3	20021118
US 2002-428515P	P	20021122
US 2002-429515P	P	20021126
US 2002-437516P	P	20021230
US 2003-439282P	P	20030110
US 2003-441335P	P	20030121
US 2003-444315P	P	20030131
US 2003-451213P	P	20030228
US 2003-378956	A2	20030303
US 2003-456027P	P	20030318
US 2003-456608P	P	20030321
US 2003-459501P	P	20030401
US 2003-463962P	P	20030418
US 2003-449307	A2	20030530
US 2003-601092	A2	20030620
WO 2003-US19574	A2	20030620
US 2003-486713P	P	20030711
US 2003-487064P	P	20030711
US 2003-637829	A2	20030808
WO 2003-US27772	A2	20030904
US 2003-660202	A2	20030911
WO 2003-US41273	A2	20031224
US 2003-439283P	P	20030110

WO 2003-US28982	A2	20030916
US 2003-747742	A	20031229
WO 2003-US41642	A	20031229
WO 2004-US400	W	20040108
WO 2004-US6288	A	20040226
US 2004-548343P	P	20040227

AB The present invention provides a pharmaceutical composition comprising a propylene glycol solvate of a drug which is hygroscopic or has low aqueous solubility It has surprisingly been found that by using propylene glycol to form a solvate of a hygroscopic drug, the hygroscopicity of the drug is decreased and/or the stability and aqueous solubility is increased. The drug is therefore much easier to formulate and store than its counterpart untreated or hydrated form.

IT 57-55-6, Propylene glycol, biological studies
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(pharmaceutical propylene glycol solvate compns. and method for preparation thereof)

RN 57-55-6 HCAPLUS

CN 1,2-Propanediol (CA INDEX NAME)



L13 ANSWER 5 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1251802 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER: 146:33009
TITLE: Injections containing COX II inhibitors and NSAID for analgesic and antiinflammatory action
INVENTOR(S): Jain, Rajesh; Jindal, Kour Chand; Singh, Sukhjeet; Boldhane, Sanjay
PATENT ASSIGNEE(S): Panacea Biotec Ltd., India
SOURCE: PCT Int. Appl., 33pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006126214	A2	20061130	WO 2006-IN177	20060525
WO 2006126214	A3	20070607		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
IN 2005DE01357	A	20061208	IN 2005-DE1357	20050527
AU 2006250765	A1	20061130	AU 2006-250765	20060525

CA 2609242	A1	20061130	CA 2006-2609242		20060525
KR 2008016689	A	20080221	KR 2007-730585		20071227
PRIORITY APPLN. INFO.:			IN 2005-DE1357	A	20050527
			WO 2006-IN177	W	20060525

AB Novel and highly stable injectable pharmaceutical compns. comprising at least one cyclooxygenase-II enzyme (COX-II) inhibitor or non-steroidal anti-inflammatory drug (NSAID) or COX/LOX inhibitor, or its tautomeric forms, analogs, isomers, polymorphs, solvates, prodrugs or salts thereof as active ingredient suitable for parenteral administration preferably by i.m. or i.v. route; process of preparing such compns. and therapeutic methods of using such compns. are provided. The analgesic and anti-inflammatory injectable compns. of the present invention are very useful in mammals particularly in humans for the treatment of acute painful conditions like one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurol. pain and pain associated with sciatica and spondylitis, and the like, and/or chronic painful conditions, and/or a variety of painful and inflammatory conditions like postoperative pain, primary dysmenorrhea and painful osteoarthritis, and/or other associated disorders such as inflammation, fever, allergy, or the like. For example, injections contained nimesulide, PEG, propylene glycol, glycine and sodium hydroxide.

IT 57-55-6, Propylene glycol, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(injections containing COX II inhibitors and NSAID for analgesic and antiinflammatory action)

RN 57-55-6 HCAPLUS

CN 1,2-Propanediol (CA INDEX NAME)



L13 ANSWER 6 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:844631 HCAPLUS <<LOGINID::20080310>>

DOCUMENT NUMBER: 145:256166

TITLE: Transmucosal administration of drug compositions for treating and preventing disorders in animals

INVENTOR(S): Heit, Mark; Benitz, Antonio; Steadman, Dennis; Petrick, David

PATENT ASSIGNEE(S): Velcera Pharmaceuticals, USA; Novadel Pharma, Inc.

SOURCE: PCT Int. Appl., 128pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006089082	A2	20060824	WO 2006-US5575	20060217
WO 2006089082	A3	20070712		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU 2006214166	A1	20060824	AU 2006-214166		20060217
CA 2597956	A1	20060824	CA 2006-2597956		20060217
US 2006239928	A1	20061026	US 2006-356451		20060217
EP 1848270	A2	20071031	EP 2006-735301		20060217

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU

PRIORITY APPLN. INFO.:	US 2005-653964P	P 20050217
	US 2005-661920P	P 20050316
	US 2005-664181P	P 20050323
	US 2005-664183P	P 20050323
	US 2005-664938P	P 20050325
	US 2005-664939P	P 20050325
	US 2005-665525P	P 20050328
	US 2005-669888P	P 20050411
	US 2005-670651P	P 20050413
	US 2005-693942P	P 20050627
	WO 2006-US5575	W 20060217

AB The invention includes compns. for transmucosal administration to an animal comprising at least one active agent and a pharmaceutically acceptable carrier. A preferred active agent is selected from the group consisting of meloxicam, carprofen, enrofloxacin, clemastine, diphenhydramine, digoxin, levothyroxine, cyclosporine, ondansetron, lysine, zolpidem, propofol, nitenpyram, ivermectin, milbemycin, and pharmaceutically acceptable salts, solvates and esters thereof. In another embodiment, the invention includes methods of treating or preventing a condition in an animal comprising transmucosally administering a composition comprising a therapeutically or prophylactically effective amount of an active agent and a pharmaceutically acceptable carrier. For example, composition was prepared containing meloxicam 4.67 mg, boric acid 0.77 mg, potassium chloride 0.93 mg, polyvinyl alc. 5 mg, Et alc. 150 mg, sodium hydroxide 1.08 mg and water 837.57.

IT 57-55-6, Propylene glycol, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transmucosal administration of drug compns. for treating and preventing disorders in animals)

RN 57-55-6 HCAPLUS

CN 1,2-Propanediol (CA INDEX NAME)



L13 ANSWER 7 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2006:608688 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER:	145:70090
TITLE:	Polymorphic forms of levosalbutamol and pharmaceutical compositions containing them
INVENTOR(S):	Lulla, Amar; Malhotra, Geena; Rao, Dharmaraj Ramchandra; Kankan, Rajendra Narayanrao; Chaudhary, Alka
PATENT ASSIGNEE(S):	Cipla Limited, India; Turner, Craig Robert
SOURCE:	PCT Int. Appl., 64 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006064283	A1	20060622	WO 2005-GB4935	20051219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005315337	A1	20060622	AU 2005-315337	20051219
CA 2591406	A1	20060622	CA 2005-2591406	20051219
US 2006241191	A1	20061026	US 2005-305226	20051219
EP 1828100	A1	20070905	EP 2005-843722	20051219
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
IN 2006MN00567	A	20070518	IN 2006-MN567	20060515
MX 200707378	A	20070814	MX 2007-7378	20070618
KR 2007100735	A	20071011	KR 2007-716000	20070713
CN 101124198	A	20080213	CN 2005-80048439	20070817

PRIORITY APPLN. INFO.:		
IN 2004-MU1356	A	20041217
IN 2005-MU40	A	20050114
IN 2005-MU343	A	20050324
WO 2005-GB4935	W	20051219

AB The invention provides 3 polymorphic forms of crystalline levosalbutamol sulfate designated herein as Forms (I), (II) and (III). The above crystalline levosalbutamol sulfate Forms are characterized by a powder XRD pattern. Processes for making the new polymorphic forms and pharmaceutical compns. comprising them are also provided. A pharmaceutical composition comprises a therapeutically effective isomer of salbutamol or a salt, solvate , ester, derivative or polymorph thereof, a glucocorticoid and a carrier or excipient and optionally one or more other therapeutic agents. Preferably the composition is an aerosol formulation comprising the drugs, a propellant and one or more other ingredients, such as a surfactant, cosolvent, or bulking agent. Alternatively, DPI or inhalation suspensions may be used. Thus, an inhalant formulation contained levosalbutamol sulfate 10.08 and fluticasone propionate 8.24 mg, and Propellant-227 g.

IT 57-55-6, 1,2-Propanediol, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polymorphic forms of levosalbutamol and pharmaceutical compns. containing them)

RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1049848 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER: 143:353332
TITLE: Preparation of novel pharmaceutical forms
INVENTOR(S): Hickey, Magali Bourghol; Peterson, Matthew; Almarsson, Orn; Zaworotko, Michael J.; Shattock, Tanise; McMahon, Jennifer; Bis, Joanna; Remenar, Julius; Tawa, Mark
PATENT ASSIGNEE(S): Transform Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005089511	A2	20050929	WO 2005-US9305	20050317
WO 2005089511	A3	20070222		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:		
US 2004-554834P	P	20040319
US 2004-566647P	P	20040430
US 2004-610296P	P	20040916
US 2004-637907P	P	20041221

AB Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivs. thereof are provided by the subject invention. Methods of making and using the same are also provided. Thus, donepezil and nicotinamide were dissolved in EtOH and excess of water to give donepezil tetrahydrate.

IT 57-55-6, Propylene glycol, uses
RL: NUU (Other use, unclassified); USES (Uses)
(preparation of novel pharmaceutical forms)

RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (CA INDEX NAME)



L13 ANSWER 9 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:98819 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER: 142:198250
TITLE: Medicaments for inhalation comprising an anticholinergic and a betamimetic

INVENTOR(S): Meade, Christopher John Montague; Pairet, Michel; Pieper, Michael P.; Konetzki, Ingo
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany
SOURCE: U.S. Pat. Appl. Publ., 33 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005025718	A1	20050203	US 2004-891564	20040715
CA 2534120	A1	20050217	CA 2004-2534120	20040717
WO 2005013994	A1	20050217	WO 2004-EP8013	20040717
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1651224	A1	20060503	EP 2004-741123	20040717
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007500676	T	20070118	JP 2006-521457	20040717

PRIORITY APPLN. INFO.:

EP 2003-17349	A	20030731
US 2003-508124P	P	20031002
WO 2004-EP8013	W	20040717

OTHER SOURCE(S): CASREACT 142:198250; MARPAT 142:198250
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A pharmaceutical composition comprising an anticholinergic, e.g., tropium salt I·X- (X = anion of single neg. charge; F, Cl, Br, I, sulfate, phosphate, SO3Me, NO3, maleate, OAc, citrate, fumarate, tartrate, oxalate, succinate, OBz, SO3C6H4Me-4; optionally as racemates, enantiomers, solvates and/or hydrates), quaternary ammonium salt II·X- [R = Me, Et], or alkaloid salt III·X- [A = bond, O, CH2, H2; R1, R2 = Me, Et, CH2Et, CHMe2 (optionally substituted by OH, F); R3, R4, R5, R6 = H, Me, Et, OMe, OEt, OH, F, Cl, Br, CN, CF3, NO2; R7 = H, Me, Et, OMe, OEt, CH2F, CH2CH2F, OCH2F, OCH2CH2F, CH2OH, CH2CH2OH, CF3, CH2OMe, CH2CH2OMe, CH2OEt, CH2CH2OEt, OAc, OC(:O)Et, OC(:O)CF3, F, Cl, Br], and a betamimetic, e.g., quinolone IV or its enantiomers, optionally together with a pharmaceutically acceptable excipient, the anticholinergic and the betamimetic optionally in the form of their enantiomers, mixts. of their enantiomers, their racemates, their solvates, or their hydrates, processes for preparing them, and their use in the treatment of asthma, COPD, or other inflammatory or obstructive respiratory complaints.

IT 57-55-6, Propylene glycol, uses
RL: NUU (Other use, unclassified); USES (Uses)
(inhalant co-solvent; pharmaceutical composition for inhalation comprising anticholinergic and betamimetic)

RN 57-55-6 HCAPLUS

CN 1,2-Propanediol (CA INDEX NAME)

L13 ANSWER 10 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:589401 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER: 141:128859
TITLE: Pharmaceutical propylene glycol solvate compositions
INVENTOR(S): Tawa, Mark; Almarsson, Oern; Remenar, Julius
PATENT ASSIGNEE(S): Transform Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 317 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 18
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060347	A2	20040722	WO 2003-US41642	20031229
WO 2004060347	A3	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6559293	B1	20030506	US 2002-232589	20020903
WO 2004000284	A1	20031231	WO 2003-US19574	20030620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005025791	A1	20050203	US 2003-601092	20030620
WO 2004026235	A2	20040401	WO 2003-US28982	20030916
WO 2004026235	A3	20040805		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2004061433 A1 20040722 WO 2003-US41273 20031224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003300452 A1 20040729 AU 2003-300452 20031229
WO 2004089313 A2 20041021 WO 2004-US9947 20040331
WO 2004089313 A3 20051124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2006140985 A1 20060629 US 2005-541703 20050708
US 2006223794 A1 20061005 US 2005-551014 20050929
PRIORITY APPLN. INFO.: US 2002-232589 A 20020903
US 2002-437516P P 20021230
US 2003-441335P P 20030121
US 2003-456027P P 20030318
US 2003-456608P P 20030321
US 2003-459501P P 20030401
US 2003-601092 A 20030620
WO 2003-US19574 A 20030620
US 2003-486713P P 20030711
WO 2003-US28982 A 20030916
WO 2003-US41273 A 20031224
US 2002-356764P P 20020215
US 2002-360768P P 20020301
US 2002-380288P P 20020515
US 2002-384152P P 20020531
US 2002-390881P P 20020621
US 2002-406974P P 20020830
US 2002-412459P P 20020920
US 2002-426275P P 20021114
US 2002-427086P P 20021115
US 2002-295995 A3 20021118
US 2002-428515P P 20021122
US 2002-429515P P 20021126
US 2003-439282P P 20030110
US 2003-439283P P 20030110
US 2003-444315P P 20030131
US 2003-451213P P 20030228
US 2003-378956 A 20030303
US 2003-463962P P 20030418
US 2003-449307 A 20030530
US 2003-487064P P 20030711
US 2003-637829 A 20030808
WO 2003-US27772 A2 20030904
US 2003-660202 A2 20030911

US 2003-747742	A	20031229
US 2004-747742	A1	20031229
WO 2003-US341642	A	20031229
WO 2003-US41642	W	20031229
WO 2004-US400	W	20040108
WO 2004-US6288	A	20040226
US 2004-548343P	P	20040227
WO 2004-US9947	W	20040331

AB The invention relates to pharmaceutical compns. comprising propylene glycol solvates of active pharmaceutical ingredients (APIs) which are hygroscopic or has low aqueous solubility The composition comprises solvate characterized by (i) the mole ratio of propylene glycol to API in the range of 0.25 to 2; (ii) a crystalline form, (iii) a powder X-ray diffraction spectrum which differs from the corresponding powder X-ray diffraction spectrum of the unsolvated API by at least one property, (iv) stability to temps. of up to 50° under a stream of gas in a thermogravimetric anal. apparatus, (v) the API is optionally in the form of a metal salt, such as an alkali or an alkaline earth metal salt, (vi) the API has low aqueous solubility and is selected from steroid drugs, and (vii) the composition further comprises a pharmaceutically-acceptable diluent, excipient or carrier. A method for preparing a propylene glycol solvate of an API comprises (a) contacting propylene glycol with an API in solution, (b) crystallizing a propylene glycol solvate of the API from the solution, and (c) isolating the solvate. For example, to a solution of celecoxib (253 mg, 0.664 mmol) in di-Et ether (6 mL) was added propylene glycol (0.075 mL, 102 mmol). To the clear solution was added potassium t-butoxide in THF (1 M, 0.66 mL, 0.66 mmol). Crystals immediately began to form and after 5 min the solid had completely crystallized The crystalline salt form was found to be a 1:1 propylene glycol solvate of celecoxib potassium salt.

IT 57-55-6, Propylene glycol, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and compns. of propylene glycol solvates with hygroscopic or low soluble drugs)

RN 57-55-6 HCAPLUS

CN 1,2-Propanediol (CA INDEX NAME)



L13 ANSWER 11 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2003:837083 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER:	139:341650
TITLE:	Medicaments containing betamimetic drugs and a novel anticholinesterase drug for treating respiratory tract diseases
INVENTOR(S):	Banholzer, Rolf; Meade, Christopher John Montague; Meissner, Helmut; Morschhaeuser, Gerd; Pairet, Michel; Pieper, Michael P.; Pohl, Gerald; Reichl, Richard; Speck, Georg; Konetzki, Ingo
PATENT ASSIGNEE(S):	Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
SOURCE:	PCT Int. Appl., 45 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	German
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087097	A1	20031023	WO 2003-EP3669	20030409
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10256317	A1	20031023	DE 2002-10256317	20021203
US 2004010003	A1	20040115	US 2003-395501	20030324
CA 2481468	A1	20031023	CA 2003-2481468	20030409
AU 2003232201	A1	20031027	AU 2003-232201	20030409
EP 1497289	A1	20050119	EP 2003-746158	20030409
EP 1497289	B1	20050824		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009185	A	20050215	BR 2003-9185	20030409
CN 1646527	A	20050727	CN 2003-808330	20030409
AT 302774	T	20050915	AT 2003-746158	20030409
JP 2005529111	T	20050929	JP 2003-584053	20030409
EP 1586574	A1	20051019	EP 2005-10708	20030409
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PT 1497289	T	20051130	PT 2003-746158	20030409
ES 2248767	T3	20060316	ES 2003-746158	20030409
NZ 536337	A	20070531	NZ 2003-536337	20030409
ZA 2004006881	A	20060628	ZA 2004-6881	20040830
NO 2004004107	A	20041104	NO 2004-4107	20040927
IN 2004DN02916	A	20070413	IN 2004-DN2916	20040928
MX 2004PA09916	A	20050503	MX 2004-PA9916	20041008
PRIORITY APPLN. INFO.:			DE 2002-10216428	A 20020412
			DE 2002-10256317	A 20021203
			US 2002-386160P	P 20020605
			EP 2003-746158	A3 20030409
			WO 2003-EP3669	W 20030409

OTHER SOURCE(S): MARPAT 139:341650
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to novel medicament compns. based on long-acting β2 agonists and salts I·X- [X = simple anion (Cl, Br, I, sulfate, phosphate, O3SMe, NO3, maleate, OAc, citrate, fumarate, tartrate, oxalate, succinate, O2CPh, OTs)], of a novel anticholinesterase drug I, to methods for the production of these compns. and their use in treating respiratory tract diseases. The invention also relates to the combination of I with one or more biomimetics II [R1, R2 = H, C1-4-alkyl; R3, R4 = H, C1-4-alkyl, O-(C1-4-alkyl), (C1-4-alkylene)-O-(C1-4-alkyl); R3R4 = C1-4-alkylene, O-(C1-4-alkylene)-O], their enantiomers, mixts., racemates, solvates, hydrates or with salmeterol, formoterol or their acid addition salts. Thus, an example inhalation powder formulation comprises I·Br- and II·HO2CCH:CHCO2H-(Z) (R1 = R2 = H, R3 = R4 = Et)

and lactose.
IT 57-55-6, Propylene glycol, uses
RL: NUU (Other use, unclassified); USES (Uses)
(inhalant co-solvent; medicaments containing betamimetic drugs and a novel anticholinesterase drug for treating respiratory tract diseases)
RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:923625 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER: 136:58810
TITLE: Pharmaceutical anti-inflammatory aerosol formulation containing a hydrofluoroalkane propellant
INVENTOR(S): Armour, Duncan Robert; Brown, David; Congreve, Miles Stuart; Gore, Paul Martin; Green, Darren Victor Steven; Holman, Stuart; Jack, Torquil Iain MacLean; Mason, Andrew McMurtrie; Morriss, Karen; Ramsden, Nigel Grahame; Thomas, Marian; Ward, Peter
PATENT ASSIGNEE(S): Glaxo Group Limited, UK; et al.
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001095925	A1	20011220	WO 2001-GB2613	20010615
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1289539	A1	20030312	EP 2001-938435	20010615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004503505	T	20040205	JP 2002-510103	20010615
PRIORITY APPLN. INFO.:			GB 2000-14881	A 20000616
			WO 2001-GB2613	W 20010615

AB The present invention relates to a pharmaceutical aerosol formulation comprising a hydrofluoroalkane (HFA) propellant having dissolved therein particulate (2S)-3-[4-({[4-(aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-[((2S)-4-methyl-2-{[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino]propanoic acid (I) or a salt or solvate thereof. Methods and uses of the formulation in the treatment of respiratory disorders are also described, as are canisters and metered dose inhalers containing said

formulation. For example, I was prepared, formulated as aerosol containing 1% I, 10% ethanol, and 1,1,1,2-tetrafluoroethane up to 100% (by weight), and the formulation was filled into an aluminum canister, to obtain a metered dose inhaler with about 120 actuations.

IT 57-55-6, Propylene glycol, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation and aerosol formulation of anti-inflammatory leucyl-tyrosine derivative for treatment of respiratory disorders)

RN 57-55-6 HCAPLUS

CN 1,2-Propanediol (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 13 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:747580 HCAPLUS <<LOGINID::20080310>>

DOCUMENT NUMBER: 135:278052

TITLE: Oily compositions containing highly fat-soluble drugs

INVENTOR(S): Nishihara, Yoshitaka; Kinoshita, Haruki; Yoshikawa, Takayoshi

PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan

SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074331	A1	20011011	WO 2001-JP2621	20010329
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001044614	A	20011015	AU 2001-44614	20010329
CA 2404381	A1	20020926	CA 2001-2404381	20010329
EP 1273287	A1	20030108	EP 2001-917589	20010329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 3831253	B2	20061011	JP 2001-572076	20010329
MX 2002PA09763	A	20030327	MX 2002-PA9763	20021003
US 2003149061	A1	20030807	US 2002-240602	20021003
PRIORITY APPLN. INFO.:			JP 2000-102272 A	20000404
			WO 2001-JP2621 W	20010329

OTHER SOURCE(S): MARPAT 135:278052

AB Disclosed are oily compns. which contain as the principal agent highly fat-soluble drugs, pharmaceutically acceptable salts and solvates thereof and further contain (1) a triester of glycerol

with a medium-chain fatty acid and/or an ester of propylene glycol with a medium-chain fatty acid, (2) a triester of glycerol with a long-chain fatty acid, and (3) a surfactant. An emulsion contained 3''-fluoro-2',3',5',6'-tetramethyl-N-(3-methyl-2-butenyl)-4''-[(3-methyl-2-butenyl)oxy]-[1,1':4',1''-terphenyl]-4-amine 10 %, Miglyol-812 60 %, avocado oil 10 %, and sorbitan monopalmitate 20 %.

IT 57-55-6D, Propylene glycol, esters with medium-chain fatty acids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oily compns. containing highly fat-soluble drugs)

RN 57-55-6 HCAPLUS

CN 1,2-Propanediol (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 14 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:247477 HCAPLUS <<LOGINID::20080310>>

DOCUMENT NUMBER: 131:92418

TITLE: Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing

AUTHOR(S): Masson, Mar; Loftsson, Thorsteinn; Masson, Gisli; Stefansson, Einar

CORPORATE SOURCE: Department of Pharmacy, University of Iceland, P.O Box 7210, Reykjavik, IS-107, Iceland

SOURCE: Journal of Controlled Release (1999), 59(1), 107-118
CODEN: JCREEC; ISSN: 0168-3659

PUBLISHER: Elsevier Science Ireland Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB It is well known that cyclodextrins can enhance the permeation of poorly soluble drugs through biol. membranes. However, the permeability will decrease if cyclodextrin is added in excess of the concentration needed to solvate the drug. The mechanism of cyclodextrin effect on drug permeability has not been fully explained. The effect of cyclodextrins cannot be explained as solely due to increased solubility of the drug in the aqueous donor phase nor can it be explained by assuming that cyclodextrins act as classical permeation enhancers, i.e. by decreasing the barrier function of the lipophilic membrane. In the present work, we modeled the effect of cyclodextrins in terms of mixed barrier consisting of both diffusion and membrane controlled diffusion, where the diffusion of the drug in the aqueous diffusion layer is significantly slower than in the bulk of the donor. This diffusion model is described by simple math. equation where the properties of the system are expressed in terms of 2 consts. PM/Kd and M1/2. Data for the permeation of hydrocortisone through hairless mouse skin in the presence of various cyclodextrins, and cyclodextrin polymer mixts., were fitted to obtain values for these 2 consts. The rise in flux with increased cyclodextrin complex concentration and fall with excess cyclodextrin was accurately predicted. Data for the permeation of drugs through a semi-permeable cellophane membrane could also be fitted to the equation. Cyclodextrins act as permeation enhancers carrying the drug through the aqueous barrier, from the bulk solution towards the lipophilic surface of biol. membranes, where the drug mols. partition from the complex into the lipophilic membrane.

IT 57-55-6D, 1,2-Propanediol, cyclodextrin ethers, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); THU

(Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(cyclodextrins as permeation enhancers of drugs)
RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 15 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:49473 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER: 114:49473
TITLE: Influence of solvent composition on the solubilities and solid-state properties of the sodium salts of some drugs
AUTHOR(S): Rubino, Joseph T.; Thomas, Elizabeth
CORPORATE SOURCE: Sch. Pharm., Univ. North Carolina, Chapel Hill, NC, 27599-7360, USA
SOURCE: International Journal of Pharmaceutics (1990), 65(1-2), 141-5
CODEN: IJPHDE; ISSN: 0378-5173
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The solubilities of the Na salts of some sulfonamides, barbiturates and hydantoins were determined in mixts. of propylene glycol and water. In many cases, the solubilities of the salts in the mixed solvents were lower than those in water, however, several compds. exhibited enhanced solubilities in the mixed solvents. This unexpected increase in solubility was not related to the lipophilicity of the acidic forms of the drugs and occurred in at least one member of each group of compds. Anal. of the solid phase which had been equilibrated with each solvent indicated the formation of crystal hydrates for most of the solutes, and in at least one instance, mixed solvates. These compds. could be categorized on the basis of their desolvation temps. Those compds. with low temps. of desolvation had increased solubilities in propylene glycol-water mixts. while compds. with high desolvation temps. had decreased solubilities in the mixed solvents. These data indicate that crystal hydrate formation plays a significant role in determining if a cosolvent can be used to enhance the solubilities of certain sodium salts.
IT 57-55-6, Propylene glycol, properties
RL: PRP (Properties)
(drug sodium salts solubility in aqueous solns. of)
RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (CA INDEX NAME)



L13 ANSWER 16 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:83994 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER: 112:83994

TITLE: Lipid-protein-partitioning (LPP) theory of skin enhancer activity: finite dose technique
AUTHOR(S): Goodman, Michael; Barry, Brian W.
CORPORATE SOURCE: Sch. Pharm., Univ. Bradford, Bradford, BD7 1DP, UK
SOURCE: International Journal of Pharmaceutics (1989), 57(1), 29-40
CODEN: IJPHDE; ISSN: 0378-5173
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The effectiveness of pretreating human epidermis with a range of accelerants on the permeation of model drugs 5-fluorouracil (5FU) and estradiol (ES) was studied. To complement previous steady-state investigations with these materials, a finite dose technique with drug deposited as a dried film with accelerants Azone and decyl Me sulfoxide in both propylene glycol (PG) and water vehicles, oleic acid (OA) in PG, and PG were used. Following accelerant pretreatments, drug permeation was monitored for 4 days. All PG-based accelerants and PG promoted 5FU penetration, 2% Azone in PG by 80-fold and PG by 12-fold (24-h results quoted). Water and aqueous-based accelerants were relatively ineffective, 3% Azone with 0.1% Tween 20 in saline producing only a 3.7-fold increase. A similar trend occurred with ES; 5% OA in PG was the most effective pretreatment, yielding a 35-fold increase, and PG produced a 9-fold effect. The aqueous-based enhancers were ineffective. With the finite dose technique, PG pretreatment increased drug penetration, contrasting with its ineffectiveness in our previous steady-state work. The glycol may solvate the tissue when it is not fully hydrated, competing with drug for hydrogen-bonding sites. Addnl., PG may aid more drug to partition into the skin. The accelerants themselves, which probably disrupt the lipid bilayers, were more effective with PG rather than with water vehicles. As PG may solvate horny cells, this suggests that both drugs may permeate the stratum corneum transcellularly to some extent. The 3 features of skin penetration enhancer activity (Lipid interaction, Protein alteration and Partitioning phenomena) represent the essential aspects of the LPP theory.

IT 57-55-6, Propylene glycol, biological studies
RL: BIOL (Biological study)
(penetration enhancer, skin pretreatment with, drug permeation response to, lipid-protein-partitioning theory in study of)

RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 20:40:11 ON 10 MAR 2008)

     FILE 'HCAPLUS' ENTERED AT 20:40:35 ON 10 MAR 2008
               E US20070015841/PN 25
L1             7 S E3

     FILE 'STNGUIDE' ENTERED AT 20:41:33 ON 10 MAR 2008

     FILE 'REGISTRY' ENTERED AT 20:43:14 ON 10 MAR 2008
L2            13 S  639010-33-6 OR  639010-34-7 OR  639010-35-8 OR 639010-36-9 O
L3             7 S 9004-65-3 OR  9004-96-0 OR 106392-12-5 OR 162011-90-7 OR  169
```

```
L4           20 S L2-L3

     FILE 'HCAPLUS' ENTERED AT 20:43:48 ON 10 MAR 2008
L5       132496 S L4
L6            4 S L5 AND L1

     FILE 'STNGUIDE' ENTERED AT 20:44:12 ON 10 MAR 2008

     FILE 'HCAPLUS' ENTERED AT 20:47:58 ON 10 MAR 2008
                E CELECOXIB+ALL/CT
L7       512737 S (CELECOXIB OR "HEALTH PRODUCTS" OR "DRUGS" OR "ANTI-INFLAMMAT
                E CELECOXIB+ALL/CT
L8       555488 S (CELECOXIB OR "CYCLIC COMPOUNDS" OR "HETEROCYCLIC COMPOUNDS"
                E CELECOXIB+ALL/CT
L9         3288 S (CELECOXIB OR "CELECOXIB" OR "BENZENESULFONAMIDE, 4-(5-(4-MET
L10      568599 S L7-L9
                E "57-55-6"/BI,RN 25
L11       30485 S E3 OR E5 OR E6 OR E7
L12        2399 S L10 AND L11
L13          16 S L12 AND SOLVATE

     FILE 'STNGUIDE' ENTERED AT 20:51:13 ON 10 MAR 2008
L14           0 S L13 AND L5

L15  ANSWER 1 OF 8  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2007:1238781  HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER:          147:491657
TITLE:                    Novel low dose pharmaceutical compositions comprising
                          nimesulide, preparation and use thereof
INVENTOR(S):              Jain, Rajesh; Jindal, Kour Chand
PATENT ASSIGNEE(S):       Panacea Biotec Ltd., India
SOURCE:                   PCT Int. Appl., 40pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
     WO 2007122637        A1    20071101    WO 2007-IN162          20070423
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,
             GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,
             KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK,
             MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
             RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
     IN 2006DE01033        A     20080118    IN 2006-DE1033         20060424
PRIORITY APPLN. INFO.:                     IN 2006-DE1033      A  20060424
AB   Low dose pharmaceutical dosage form comprising nimesulide or its
     pharmaceutically acceptable salts, esters, solvates or hydrates
     thereof, along with one or more pharmaceutically acceptable excipient(s)
     for once- or twice-a-day administration are provided.  The present
     invention also provides process of preparing such dosage forms and
     therapeutic methods of using such dosage forms.  The low dose compns. are
     designed to exhibit bioavailability with reduced side effects, which is
```

effective in the treatment of NSAID indicated disorders particularly, which require long-term treatment regimens such as arthritis. Such compns. reduce the cost of therapy in diseases, which require long-term therapies, are easy to manufacture, and also result in the reduction of dose related side effects associated with nimesulide therapy. Thus, tablets containing nimesulide 75.0 mg, microcryst. cellulose 285.0 mg, lactose 100.0 mg, croscarmellose sodium 20.0 mg, hydrogenated castor oil 7.5 mg, talc 7.5 mg, and colloidal silica 7.5 mg were prepared by wet granulation using iso-Pr alc. and compression.

IT 57-55-6, Propylene glycol, biological studies 57-55-6D, Propylene glycol, C8-10 diesters 9004-65-3, Hydroxypropyl methyl cellulose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(low-dose nimesulide compns. optionally in combination with other agents for treatment of inflammation and related disorders)

RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (CA INDEX NAME)



RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (CA INDEX NAME)



RN 9004-65-3 HCAPLUS
CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O



CM 3

CRN 57-55-6
CMF C3 H8 O2

IT 9004-34-6, Cellulose, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(microcryst.; low-dose nimesulide compns. optionally in combination with other agents for treatment of inflammation and related disorders)
RN 9004-34-6 HCAPLUS
CN Cellulose (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:845664 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER: 147:220080
TITLE: Novel oral pharmaceutical compositions for poorly absorbable drugs comprising absorbents, bioadhesive polymers, and permeation enhancers
INVENTOR(S): Jain, Rajesh; Jindal, Kour Chand; Devarajan, Sampath Kumar
PATENT ASSIGNEE(S): Panacea Biotec Ltd., India
SOURCE: PCT Int. Appl., 41pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007086078	A2	20070802	WO 2007-IN29	20070129
WO 2007086078	A3	20071213		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: IN 2006-DE242 A 20060130
AB Novel oral pharmaceutical compns. comprising (i) at least one active agent(s) or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates, analogs, enantiomers, tautomeric forms or mixts. thereof; (ii) at least one permeation enhancer(s); (iii) at least one adsorbent(s), (iv) at least one bioadhesive polymer(s); (v) optionally at least one acid soluble polymer(s), and (vi) optionally one or more other pharmaceutically acceptable excipient(s) are provided. The active agents exhibit poor or incomplete absorption, are preferably absorbed from the upper part of the gastrointestinal tract, and/or exhibit dissoln. rate with limited gastrointestinal absorption. The compns. particularly target the absorption window of the active agent(s) delivering the active agent

at the absorption site preferably over an extended period of time to enhance their bioavailability. Preferably the compns. are in the gastro-adhesive modified release form and/or fast disintegrating dosage form which release the active agent(s) over an extended period of time. Also provided are processes of preparation of such novel compns. and methods of using them. Thus, tablets were prepared comprising (a) a core composition containing amoxicillin trihydrate 500.0, glyceryl monocaprylate 60.0, microcryst. cellulose (Avicel PH 102) 100.0, sodium alginate 100.0, hydroxypropyl Me cellulose 50.0, anhydrous lactose (Pharmatose DCL 21) 42.3, and magnesium stearate 5.0, (b) a coating composition containing Eudragit E100 85.5, triacetin 8.5, talc 37.7, isopropanol as needed, and acetone as needed, and (c) an extragranular composition containing calcium CM-cellulose 100.0, Avicel PH 102 100.0, and magnesium stearate 10.0 mg, resp. The cores, prepared by dry granulation, were coated, mixed with the extragranular composition and compressed into tablets.

IT 9004-34-6, Cellulose, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(microcryst.; oral pharmaceutical compns. for poorly absorbable drugs comprising adsorbent, bioadhesive polymer and permeation enhancers)
RN 9004-34-6 HCAPLUS
CN Cellulose (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 57-55-6, Propylene glycol, biological studies 9004-34-6D, Cellulose, ethers 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral pharmaceutical compns. for poorly absorbable drugs comprising adsorbent, bioadhesive polymer and permeation enhancers)
RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (CA INDEX NAME)



RN 9004-34-6 HCAPLUS
CN Cellulose (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9004-64-2 HCAPLUS
CN Cellulose, 2-hydroxypropyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2

RN 9004-65-3 HCAPLUS
CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O

CM 3

CRN 57-55-6
CMF C3 H8 O2

L15 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:63611 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER: 146:148846
TITLE: Pharmaceutical propylene glycol solvate compositions and method for preparation thereof
INVENTOR(S): Tawa, Mark; Almarsson, Orn; Remenar, Julius
PATENT ASSIGNEE(S): Transform Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 33pp., Cont.-in-part of Appl. No. PCT/US03/41273.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 18
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007015841	A1	20070118	US 2003-747742	20031229
US 6559293	B1	20030506	US 2002-232589	20020903
US 2003166581	A1	20030904	US 2002-295995	20021118
US 6699840	B2	20040302		

US 2003224006 A1 20031204 US 2003-378956 20030303
US 2004019211 A1 20040129 US 2003-449307 20030530
US 7078526 B2 20060718
WO 2004000284 A1 20031231 WO 2003-US19574 20030620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2005025791 A1 20050203 US 2003-601092 20030620
US 2004053853 A1 20040318 US 2003-637829 20030808
WO 2004078161 A1 20040916 WO 2003-US27772 20030904
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2007026078 A1 20070201 US 2003-660202 20030911
WO 2004061433 A1 20040722 WO 2003-US41273 20031224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2004063152 A2 20040729 WO 2004-US400 20040108
WO 2004063152 A3 20041111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ
WO 2004089313 A2 20041021 WO 2004-US9947 20040331
WO 2004089313 A3 20051124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
ZA 2004007377 A 20051004 ZA 2004-7377 20040914
US 2006140985 A1 20060629 US 2005-541703 20050708
PRIORITY APPLN. INFO.: US 2002-356764P P 20020215
US 2002-360768P P 20020301

US 2002-380288P	P	20020515
US 2002-384152P	P	20020531
US 2002-390881P	P	20020621
US 2002-406974P	P	20020830
US 2002-232589	A1	20020903
US 2002-426275P	P	20021114
US 2002-427086P	P	20021115
US 2002-295995	A3	20021118
US 2002-428515P	P	20021122
US 2002-429515P	P	20021126
US 2002-437516P	P	20021230
US 2003-439282P	P	20030110
US 2003-441335P	P	20030121
US 2003-444315P	P	20030131
US 2003-451213P	P	20030228
US 2003-378956	A2	20030303
US 2003-456027P	P	20030318
US 2003-456608P	P	20030321
US 2003-459501P	P	20030401
US 2003-463962P	P	20030418
US 2003-449307	A2	20030530
US 2003-601092	A2	20030620
WO 2003-US19574	A2	20030620
US 2003-486713P	P	20030711
US 2003-487064P	P	20030711
US 2003-637829	A2	20030808
WO 2003-US27772	A2	20030904
US 2003-660202	A2	20030911
WO 2003-US41273	A2	20031224
US 2003-439283P	P	20030110
WO 2003-US28982	A2	20030916
US 2003-747742	A	20031229
WO 2003-US41642	A	20031229
WO 2004-US400	W	20040108
WO 2004-US6288	A	20040226
US 2004-548343P	P	20040227

AB The present invention provides a pharmaceutical composition comprising a propylene glycol solvate of a drug which is hygroscopic or has low aqueous solubility It has surprisingly been found that by using propylene glycol to form a solvate of a hygroscopic drug, the hygroscopicity of the drug is decreased and/or the stability and aqueous solubility is increased. The drug is therefore much easier to formulate and store than its counterpart untreated or hydrated form.

IT 169590-42-5, Celecoxib
RL: RCT (Reactant); RACT (Reactant or reagent)
(pharmaceutical propylene glycol solvate compns. and method for preparation thereof)

RN 169590-42-5 HCAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



IT 57-55-6, Propylene glycol, biological studies
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(pharmaceutical propylene glycol solvate compns. and method for preparation thereof)
RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (CA INDEX NAME)



IT 639010-40-5P 919287-67-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(pharmaceutical propylene glycol solvate compns. and method for preparation thereof)
RN 639010-40-5 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, sodium salt, compd. with 1,2-propanediol, hydrate (1:1:1:3) (CA INDEX NAME)

CM 1

CRN 169590-42-5
CMF C17 H14 F3 N3 O2 S



CM 2

CRN 57-55-6
CMF C3 H8 O2

RN 919287-67-5 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, sodium salt, compd. with 1,2-propanediol (1:1:1) (CA INDEX NAME)

CM 1

CRN 169590-42-5
CMF C17 H14 F3 N3 O2 S



CM 2

CRN 57-55-6
CMF C3 H8 O2

IT 639010-33-6, Celecoxib sodium 639010-34-7, Celecoxib lithium 639010-35-8, Celecoxib potassium
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical propylene glycol solvate compns. and method for preparation thereof)
RN 639010-33-6 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 639010-34-7 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, lithium salt (1:1) (CA INDEX NAME)



● Li

RN 639010-35-8 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, potassium salt (1:1) (CA INDEX NAME)



● K

L15 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1251802 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER: 146:33009
TITLE: Injections containing COX II inhibitors and NSAID for analgesic and antiinflammatory action
INVENTOR(S): Jain, Rajesh; Jindal, Kour Chand; Singh, Sukhjeet; Boldhane, Sanjay
PATENT ASSIGNEE(S): Panacea Biotec Ltd., India
SOURCE: PCT Int. Appl., 33pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006126214	A2	20061130	WO 2006-IN177	20060525
WO 2006126214	A3	20070607		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
IN 2005DE01357	A	20061208	IN 2005-DE1357	20050527
AU 2006250765	A1	20061130	AU 2006-250765	20060525
CA 2609242	A1	20061130	CA 2006-2609242	20060525
KR 2008016689	A	20080221	KR 2007-730585	20071227
PRIORITY APPLN. INFO.:			IN 2005-DE1357 A	20050527
			WO 2006-IN177 W	20060525

AB Novel and highly stable injectable pharmaceutical compns. comprising at least one cyclooxygenase-II enzyme (COX-II) inhibitor or non-steroidal anti-inflammatory drug (NSAID) or COX/LOX inhibitor, or its tautomeric forms, analogs, isomers, polymorphs, solvates, prodrugs or salts

thereof as active ingredient suitable for parenteral administration preferably by i.m. or i.v. route; process of preparing such compns. and therapeutic methods of using such compns. are provided. The analgesic and anti-inflammatory injectable compns. of the present invention are very useful in mammals particularly in humans for the treatment of acute painful conditions like one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurol. pain and pain associated with sciatica and spondylitis, and the like, and/or chronic painful conditions, and/or a variety of painful and inflammatory conditions like postoperative pain, primary dysmenorrhea and painful osteoarthritis, and/or other associated disorders such as inflammation, fever, allergy, or the like. For example, injections contained nimesulide, PEG, propylene glycol, glycine and sodium hydroxide.

IT 57-55-6, Propylene glycol, biological studies 162011-90-7, Rofecoxib 169590-41-4, Deracoxib 169590-42-5, Celecoxib 181695-72-7, Valdecoxib 202409-33-4, Etoricoxib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(injections containing COX II inhibitors and NSAID for analgesic and antiinflammatory action)

RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (CA INDEX NAME)



RN 162011-90-7 HCAPLUS
CN 2(5H)-Furanone, 4-[4-(methylsulfonyl)phenyl]-3-phenyl- (CA INDEX NAME)



RN 169590-41-4 HCAPLUS
CN Benzenesulfonamide, 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 169590-42-5 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 181695-72-7 HCAPLUS
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (CA INDEX NAME)



RN 202409-33-4 HCAPLUS
CN 2,3'-Bipyridine, 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



L15 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1049848 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER: 143:353332
TITLE: Preparation of novel pharmaceutical forms
INVENTOR(S): Hickey, Magali Bourghol; Peterson, Matthew; Almarsson, Orn; Zaworotko, Michael J.; Shattock, Tanise; McMahon, Jennifer; Bis, Joanna; Remenar, Julius; Tawa, Mark
PATENT ASSIGNEE(S): Transform Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005089511	A2	20050929	WO 2005-US9305	20050317
WO 2005089511	A3	20070222		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2004-554834P	P	20040319
US 2004-566647P	P	20040430
US 2004-610296P	P	20040916
US 2004-637907P	P	20041221

AB Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivs. thereof are provided by the subject invention. Methods of making and using the same are also provided. Thus, donepezil and nicotinamide were dissolved in EtOH and excess of water to give donepezil tetrahydrate.
IT 57-55-6, Propylene glycol, uses
RL: NUU (Other use, unclassified); USES (Uses)
(preparation of novel pharmaceutical forms)
RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (CA INDEX NAME)



IT 639010-42-7P, Celecoxib sodium hydrate
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel pharmaceutical forms)
RN 639010-42-7 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, monosodium salt, hydrate (9CI) (CA INDEX NAME)



IT 639010-33-6, Celecoxib sodium
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(preparation of novel pharmaceutical forms)
RN 639010-33-6 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, sodium salt (1:1) (CA INDEX NAME)



L15 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:589401 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER: 141:128859
TITLE: Pharmaceutical propylene glycol solvate compositions
INVENTOR(S): Tawa, Mark; Almarsson, Oern; Remenar, Julius
PATENT ASSIGNEE(S): Transform Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 317 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 18
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060347	A2	20040722	WO 2003-US41642	20031229
WO 2004060347	A3	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6559293	B1	20030506	US 2002-232589	20020903
WO 2004000284	A1	20031231	WO 2003-US19574	20030620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005025791	A1	20050203	US 2003-601092	20030620
WO 2004026235	A2	20040401	WO 2003-US28982	20030916
WO 2004026235	A3	20040805		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004061433	A1	20040722	WO 2003-US41273	20031224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2003300452	A1	20040729	AU	2003-300452		20031229
WO	2004089313	A2	20041021	WO	2004-US9947		20040331
WO	2004089313	A3	20051124				

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

US	2006140985	A1	20060629	US	2005-541703		20050708
US	2006223794	A1	20061005	US	2005-551014		20050929

PRIORITY APPLN. INFO.:

US	2002-232589	A	20020903
US	2002-437516P	P	20021230
US	2003-441335P	P	20030121
US	2003-456027P	P	20030318
US	2003-456608P	P	20030321
US	2003-459501P	P	20030401
US	2003-601092	A	20030620
WO	2003-US19574	A	20030620
US	2003-486713P	P	20030711
WO	2003-US28982	A	20030916
WO	2003-US41273	A	20031224
US	2002-356764P	P	20020215
US	2002-360768P	P	20020301
US	2002-380288P	P	20020515
US	2002-384152P	P	20020531
US	2002-390881P	P	20020621
US	2002-406974P	P	20020830
US	2002-412459P	P	20020920
US	2002-426275P	P	20021114
US	2002-427086P	P	20021115
US	2002-295995	A3	20021118
US	2002-428515P	P	20021122
US	2002-429515P	P	20021126
US	2003-439282P	P	20030110
US	2003-439283P	P	20030110
US	2003-444315P	P	20030131
US	2003-451213P	P	20030228
US	2003-378956	A	20030303
US	2003-463962P	P	20030418
US	2003-449307	A	20030530
US	2003-487064P	P	20030711
US	2003-637829	A	20030808
WO	2003-US27772	A2	20030904
US	2003-660202	A2	20030911
US	2003-747742	A	20031229
US	2004-747742	A1	20031229
WO	2003-US341642	A	20031229
WO	2003-US41642	W	20031229
WO	2004-US400	W	20040108
WO	2004-US6288	A	20040226
US	2004-548343P	P	20040227
WO	2004-US9947	W	20040331

AB The invention relates to pharmaceutical compns. comprising propylene glycol solvates of active pharmaceutical ingredients (APIs) which are hygroscopic or has low aqueous solubility The composition comprises solvate characterized by (i) the mole ratio of propylene glycol to API in the range of 0.25 to 2; (ii) a crystalline form, (iii) a powder X-ray diffraction spectrum which differs from the corresponding powder X-ray diffraction spectrum of the unsolvated API by at least one property, (iv) stability to temps. of up to 50° under a stream of gas in a thermogravimetric anal. apparatus, (v) the API is optionally in the form of a metal salt, such as an alkali or an alkaline earth metal salt, (vi) the API has low aqueous solubility and is selected from steroid drugs, and (vii) the composition further comprises a pharmaceutically-acceptable diluent, excipient or carrier. A method for preparing a propylene glycol solvate of an API comprises (a) contacting propylene glycol with an API in solution, (b) crystallizing a propylene glycol solvate of the API from the solution, and (c) isolating the solvate. For example, to a solution of celecoxib (253 mg, 0.664 mmol) in di-Et ether (6 mL) was added propylene glycol (0.075 mL, 102 mmol). To the clear solution was added potassium t-butoxide in THF (1 M, 0.66 mL, 0.66 mmol). Crystals immediately began to form and after 5 min the solid had completely crystallized The crystalline salt form was found to be a 1:1 propylene glycol solvate of celecoxib potassium salt.

IT 639010-38-1P 639010-39-2P 639010-40-5P 919287-67-5P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and compns. of propylene glycol solvates with hygroscopic or low soluble drugs)

RN 639010-38-1 HCAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, monopotassium salt, compd. with 1,2-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 639010-35-8
CMF C17 H14 F3 N3 O2 S . K



● K

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 639010-39-2 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, monolithium salt, compd. with 1,2-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 639010-34-7
CMF C17 H14 F3 N3 O2 S . Li



CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 639010-40-5 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, sodium salt, compd. with 1,2-propanediol, hydrate (1:1:1:3) (CA INDEX NAME)

CM 1

CRN 169590-42-5

CMF C17 H14 F3 N3 O2 S



CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 919287-67-5 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, sodium salt, compd. with 1,2-propanediol (1:1:1) (CA INDEX NAME)

CM 1

CRN 169590-42-5
CMF C17 H14 F3 N3 O2 S



CM 2

CRN 57-55-6

CMF C3 H8 O2



IT 57-55-6, Propylene glycol, reactions 169590-42-5, Celecoxib 639010-33-6, Celecoxib sodium
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and compns. of propylene glycol solvates with hygroscopic or low soluble drugs)
RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (CA INDEX NAME)



RN 169590-42-5 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 639010-33-6 HCAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, sodium salt (1:1) (CA INDEX NAME)



L15 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:747580 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER: 135:278052
TITLE: Oily compositions containing highly fat-soluble drugs
INVENTOR(S): Nishihara, Yoshitaka; Kinoshita, Haruki; Yoshikawa, Takayoshi
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074331	A1	20011011	WO 2001-JP2621	20010329
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001044614	A	20011015	AU 2001-44614	20010329
CA 2404381	A1	20020926	CA 2001-2404381	20010329
EP 1273287	A1	20030108	EP 2001-917589	20010329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 3831253	B2	20061011	JP 2001-572076	20010329
MX 2002PA09763	A	20030327	MX 2002-PA9763	20021003
US 2003149061	A1	20030807	US 2002-240602	20021003
PRIORITY APPLN. INFO.:			JP 2000-102272 A	20000404
			WO 2001-JP2621 W	20010329

OTHER SOURCE(S): MARPAT 135:278052
AB Disclosed are oily compns. which contain as the principal agent highly fat-soluble drugs, pharmaceutically acceptable salts and solvates thereof and further contain (1) a triester of glycerol

with a medium-chain fatty acid and/or an ester of propylene glycol with a medium-chain fatty acid, (2) a triester of glycerol with a long-chain fatty acid, and (3) a surfactant. An emulsion contained 3''-fluoro-2',3',5',6'-tetramethyl-N-(3-methyl-2-butenyl)-4''-[(3-methyl-2-butenyl)oxy]-[1,1':4',1''-terphenyl]-4-amine 10 %, Miglyol-812 60 %, avocado oil 10 %, and sorbitan monopalmitate 20 %.

IT 57-55-6D, Propylene glycol, esters with medium-chain fatty acids 106392-12-5, pluronic F87
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oily compns. containing highly fat-soluble drugs)

RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (CA INDEX NAME)



RN 106392-12-5 HCAPLUS
CN Oxirane, 2-methyl-, polymer with oxirane, block (CA INDEX NAME)

CM 1

CRN 75-56-9
CMF C3 H6 O

CM 2

CRN 75-21-8
CMF C2 H4 O

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:247477 HCAPLUS <<LOGINID::20080310>>
DOCUMENT NUMBER: 131:92418
TITLE: Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing
AUTHOR(S): Masson, Mar; Loftsson, Thorsteinn; Masson, Gisli; Stefansson, Einar
CORPORATE SOURCE: Department of Pharmacy, University of Iceland, P.O Box 7210, Reykjavik, IS-107, Iceland
SOURCE: Journal of Controlled Release (1999), 59(1), 107-118
CODEN: JCREEC; ISSN: 0168-3659
PUBLISHER: Elsevier Science Ireland Ltd.

DOCUMENT TYPE: Journal
LANGUAGE: English

AB It is well known that cyclodextrins can enhance the permeation of poorly soluble drugs through biol. membranes. However, the permeability will decrease if cyclodextrin is added in excess of the concentration needed to solvate the drug. The mechanism of cyclodextrin effect on drug permeability has not been fully explained. The effect of cyclodextrins cannot be explained as solely due to increased solubility of the drug in the aqueous donor phase nor can it be explained by assuming that cyclodextrins act as classical permeation enhancers, i.e. by decreasing the barrier function of the lipophilic membrane. In the present work, we modeled the effect of cyclodextrins in terms of mixed barrier consisting of both diffusion and membrane controlled diffusion, where the diffusion of the drug in the aqueous diffusion layer is significantly slower than in the bulk of the donor. This diffusion model is described by simple math. equation where the properties of the system are expressed in terms of 2 consts. PM/Kd and M1/2. Data for the permeation of hydrocortisone through hairless mouse skin in the presence of various cyclodextrins, and cyclodextrin polymer mixts., were fitted to obtain values for these 2 consts. The rise in flux with increased cyclodextrin complex concentration and fall with excess cyclodextrin was accurately predicted. Data for the permeation of drugs through a semi-permeable cellophane membrane could also be fitted to the equation. Cyclodextrins act as permeation enhancers carrying the drug through the aqueous barrier, from the bulk solution towards the lipophilic surface of biol. membranes, where the drug mols. partition from the complex into the lipophilic membrane.

IT 57-55-6D, 1,2-Propanediol, cyclodextrin ethers, biological studies
9004-65-3D, HPMC, cyclodextrin ethers
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(cyclodextrins as permeation enhancers of drugs)

RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (CA INDEX NAME)

RN 9004-65-3 HCAPLUS
CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O

CM 3

CRN 57-55-6
CMF C3 H8 O2